key: cord-0430107-qoqjf4we
authors: McCann, Naina; O’Connor, Daniel; Lambe, Teresa; Pollard, Andrew J
title: Viral vector vaccines
date: 2022-08-31
journal: Current Opinion in Immunology
DOI: 10.1016/j.coi.2022.102210
sha: 22fe8d22753aea2243338269f5cdce58e022c3a1
doc_id: 430107
cord_uid: qoqjf4we

Over the past two years, the SARS-CoV-2 pandemic has highlighted the impact that emerging pathogens can have on global health. The development of new and effective vaccine technologies is vital in the fight against such threats. Viral vectors are a relatively new vaccine platform that relies on recombinant viruses to deliver selected immunogens into the host. In response to the SARS-CoV-2 pandemic, the development and subsequent rollout of adenoviral vector vaccines has shown the utility, impact, scalability and efficacy of this platform. Shown to elicit strong cellular and humoral immune responses in diverse populations, these vaccine vectors will be an important approach against infectious diseases in the future.

A recombinant viral vector was first used almost forty years ago as a vaccine-delivery system, when the gene for hepatitis-B surface antigen was inserted into a modified vaccinia virus [1,2]. Since then, such vaccine vectors have been widely used in veterinary medicine, but before 2020, only five had progressed through clinical trials to licensure and use in humans (Figure 1 ). However, a number of viral vector vaccines have been developed against a wide variety of infectious-disease pathogens and indeed as vaccine vectors against noninfectious diseases, particularly cancer. Owing to the SARS-CoV-2 pandemic over the last two years, there has been an expansion in the use of adenoviral vector vaccines, with doses given to billions of people worldwide. This has given enormous insight into the safety, immunogenicity and efficacy of adenoviral (Ad) vaccine technology, which will be summarised here alongside a discussion of other viral vector vaccines in use today (Table 1) . A more detailed summary of all existing licensed viral vector vaccines can be found in the Supplementary Material.

Using viral vectors as vaccine platforms allows induction of an innate immune response without the need for adjuvant. This response is key for stimulating downstream processing and later adaptive immune responses ( Figure 2 ).

The downstream patterns of signalling from Ad vector recognition involve induction of a proinflammatory response, including cytokine and chemokine production, inducing humoral and cellular responses. Importantly, Ad vectors are able to do this without causing host damage and excess cytokine production. However, the excessive induction of type-I interferons (IFNs) by Ad vectors has been associated with dampened transgene expression and reduced antibody and cellular responses [34, 35] .

Employing bioinformatic techniques to investigate transcriptional changes induced by viral vectors can give new insight into the activation of innate immune pathways by viral vectors. In a study by Sheerin et al using a mouse immunisation model, Ad vectors induced expression of genes involved in TLR2 stimulation and natural killer (NK) cell activation, whereas modified vaccinia Ankara (MVA) vectors induced expression of type-1 IFN genes [36] . Collingnon et al evaluated cytokine responses and gene expression patterns to characterise innate responses following vaccination with the ChAd155 vector vaccines in preclinical studies. The authors showed that the vaccine induced a bimodal pattern of innate cell-population changes characterised by IFN-associated signatures [37] . activation of host MHC pathways via direct and crosspresentation, inducing a robust cellular response ( Figure  3 ). The amount and duration of antigen expression correlate with CD8+ T-cell-protective immunity [35] . This potent T-cell activation has led to prior targeting of viral vector vaccines against intracellular pathogens, for example, HIV and malaria where such responses to such vaccines have correlated with protection [38] .

Recent work has confirmed the strong and durable CD4+ and CD8+ antigen-specific T-cell responses that are generated following viral vector vaccines against other pathogens such as SARS-CoV-2, Ebola and RSV [4, 11, [39] [40] [41] . The T-cell response following viral vector vaccination appears to be a Th-1-biased response, characterised by IFN-y and TNF-alpha production [27, [41] [42] [43] . Strong transgene expression by Ad vector vaccines also allows robust mono-and polyfunctional CD8+ T-cell responses [42, 44] .

These specific T-cell responses may also contribute to protection and reduction in disease severity. For example, when examining these SARS-CoV-2-specific Tcell responses following acute COVID-19 infection, they appear to inversely correlate with COVID-19 disease severity [45, 46] . Additionally, SARS-CoV-2 spike-specific follicular helper T cells correlate with neutralising antibody responses [47] . T-cell epitopes also appear to remain relatively preserved in COVID-19 variants of concern (VoC), leading to limited T-cell escape following infection or vaccination [48] [49] [50] . Given that these VoC have significant mutations in spike protein, leading to evasion of the neutralising antibody response [51] [52] [53] , the ability of Ad vector vaccines to induce a broad cellular response may be important in sustaining protection from SARS-CoV-2.

As described above, although T-cell-mediated immunity plays a role in reducing disease severity, a neutralising antibody response often correlates with protection against infection. Viral vector vaccines utilise the capacity of viruses to infect cells and induce broad immune responses. Heterologous antigens are expressed by the virus, usually from genes engineered into the viral genome, and induce antigen-specific humoral and cellular immune responses. Viral vectors themselves can be replication-deficient, replication-competent or attenuated. Replication of the virus inside cells allows ongoing amplification of the vaccine antigen and improved immunogenicity, but must be balanced against the risk of increased adverse events or even disease in the host, particularly in the immunocompromised, resulting in some preference for use of replication-incompetent vectors.

Non-neutralising antibodies are also recognised as important mediators of antipathogen immunity and in preclinical studies Fc-mediated functions were shown to contribute to protection against SARS-CoV-2 [59,60] and Ebola [61] . Systems' serology work has shown that Ad vector vaccines are able to induce antibody-dependent functional activities, including antibody-dependent neutrophil phagocytosis and antibody-dependent monocyte phagocytosis [8] . In a comparison of vaccine responses from phase-I and phase-II studies in humans using different HIV vaccines, Ad viral vectors induced a more potent IgG1 and IgG3 response than pox-virus vectors, leading to higher levels of functional antibody activity, including antibody-dependent cellular phagocytosis [62] .

Induction of a mucosal immune response is likely to play an important role in protection against respiratory pathogens. Provine Current Opinion in Immunology

Induction of innate and adaptive immune responses by adenoviral vector vaccines. Adenoviral binding occurs via the fibre protein of the Ad capsid to infection receptors, such as the coxsackievirus-adenovirus receptor (CAR) and CD46, activating entry to the cell. Secondary attachment is mediated by RGD loops on the penton protein of the Ad capsid to integrins. These binding processes themselves can trigger innate immunity, but it is the pathogen-associated molecular patterns of adenoviruses, which are recognised by cell pattern-recognition receptors (PRRs), for example, toll-like receptors (TLRs data from an aerosolised Ad5.nCoV vaccine showing two doses elicit a neutralising antibody response similar to one dose of IM injection [65] .

Pre-existing immunity against the Ad vector has the potential to reduce immunogenicity and subsequent protective effect of these vaccine vectors [66] . Multiple studies have shown that existing anti-Ad-neutralising antibodies are inversely correlated with immunological response to vaccine vector [3,6,67]. This is particularly relevant with Ad5-based vector vaccines, given their high seroprevalence in some populations [68] . However, repeated doses of Ad26 vector vaccination against HIV are able to boost both cellular and humoral immune responses, despite the presence of high Ad26-neutralising antibodies following prime vaccination [69] and following vaccination with ChAdOx1-nCoV-19-neutralising antibodies did not correlate with spike-specific antibody responses or T-cell responses following boost vaccination [12] .

To circumvent the issue of antivector immunity lessprevalent adenoviruses, nonhuman adenoviruses or chimeric adenoviruses that express modifications to the hexon major capsid protein have been increasingly used over recent years [9, [70] [71] [72] . Higher dosing regimens can also be used to overcome pre-existing vector immunity in the population, but when used with Ad5-nCoV, these higher doses caused increased reactogenicity with limited benefit in immunogenicity [3].

The use of heterologous prime-boost viral vector regimens may overcome the development of antivector immunity and be more immunogenic than homologous regimens [21, [73] [74] [75] [76] . The use of Ad26 encoding the GP of the Zaire strain of Ebola, followed by an MVA boost, was shown to provide 100% protection against lethal Ebola when administered to nonhuman primates [77] . This heterologous prime-boost regimen has now been shown to induce strong and durable immune responses in human trials persisting for at least 1 year in both endemic and nonendemic populations [26, 27] .

Combining viral vectors takes advantage of the differential ability of vectors to prime or boost immune responses. For example, adenoviruses have been shown to prime effective and durable potent B-and T-cell responses, and MVA is able to significantly boost immune responses, but elicits limited humoral responses as a prime [78, 79] . However, recent transcriptional data show that an Ad vector boost on an MVA prime appears to augment the molecular response compared with an MVA boost on an Ad prime, including stimulation of preferential TLRs and increased IFN-y signalling [36], suggesting that further exploration of this area is needed for future vaccine development.

Heterologous prime-boost vaccine schedules using different vaccine platforms have also been evaluated. For example, in vaccines against SARS-CoV-2, a prime dose of adenoviral vector vaccine has been boosted with an mRNA vaccine, which appears to increase vaccine efficacy and immunogenicity against symptomatic infection compared with homologous Ad vaccination [80] [81] [82] [83] . In preclinical studies, an MVA booster following mRNA vaccine enhanced specific T-cell responses against HIV-1 [84] .

Various methods have been used to further increase the immunogenicity of Ad vectors by enhancing transgene expression and boosting cellular responses. These include the use of endogenous promoters, co-expression of immune-stimulatory molecules and genetic-fusion adjuvants [85, 86] A further way to enhance immunogenicity of viral vectors is to increase immunogen production from vaccine vector. Self-replication via replication-competent vectors allows significant antigen production and may be necessary to induce immunity against some pathogens.

The safe use of a replication-competent VSV vector against Ebola virus, VSV-EBOV, in HIV patients, showed that such vectors can be used in immunocompromised patients [88] . An alternative is the use of single-cycle virus vectors, which allow the virus to self-amplify in one additional round of genome replication, circumvent this issue and represent a potential therapy for future viral vector vaccines [89, 90] .

Harnessing the specific tropism of certain viruses to deliver antigens to desired cell types is a further potential mechanism of improving immunogenicity against certain pathogens. For example, Viktorova et al used a recombinant Newcastle virus, a virus with mucosal tropism, to express proteins from poliovirus, which stimulated systemic and mucosal responses [91] .

Adenoviral vector vaccines have now been given to billions of people worldwide. Two vaccines (Ad26.COV2.S and ChadOx1-nCoV-19) have been associated with a very rare clotting disorder, thrombosis with thrombocytopaenia syndrome (TTS). This syndrome is characterised by the presence of antiplatelet factor-4 antibodies, although the risk factors for developing TTS and the exact pathogenesis remain unclear [92] . There may be an underlying geographical or genetic link, given variations in the rates of TTS across different populations [93] .

Over the past two years, viral vector vaccines have been used as a cornerstone of the control of SARS-CoV-2 in the pandemic, particularly in low-and middle-income countries. The application of newer techniques such as bioinformatics and systems' serology during this time has provided extensive knowledge on the immunogenicity of the adenoviral vaccine platform.

Although significant advances have been made, further understanding of the spectrum of immune responses stimulated by adenoviral vectors is still needed. Understanding of the mechanism underlying antivector immunity, particularly following repeated dosing, will be vital going forward as vaccines against multiple different pathogens are developed using the same vectors. Evaluating the long-term duration of humoral and cellular responses following widespread Ad vector administration for SARS-CoV-2, and their relationship to vaccine efficacy, will be important in providing invaluable insights into the persistence of immune responses afforded by these vaccine vectors.

Despite the excellent immunogenicity and efficacy of the approved viral vector vaccines, there remains scope to improve immunogenicity. The use of genetic or molecular adjuvants may be a useful strategy, particularly in vaccine vectors that only induce weak or short transgene expression. In addition, the use of heterologous primeboost regimens, by combining either different viral vectors or different technologies such as mRNA vaccines, has been shown to improve immunogenicity of homologous regimens, and is likely to play an important role in viral vector vaccine regimens going forward. The use of mucosal viral vector vaccines to induce site-specific immune responses may significantly improve protection, particularly against mucosal pathogens, and clinical trial data from such vaccines are eagerly awaited.

Viral vector vaccines have been a major component of the successful response to the SARS-CoV-2 pandemic. Given their safety, immunogenicity and ability to be modified and scaled up at pace, they will remain an important technology for infectious-disease control in the future.

This research did not receive any specific grant from funding agencies in the public, commercial or not-forprofit sectors. 

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.coi.2022. 102210.

Papers of particular interest, published within the period of review, have been highlighted as: Authors showed that antibody responses were higher in 28-day and 56day dosing intervals than in 21-day dosing interval and that both humoral and cellular responses persisted in 98-100% of participants at 1 year, providing further evidence that a heterologous prime-boost regimen is more immunogenic than single dose. 

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: a prospective cohort study in keyworkers

Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity

Adaptive immunity to SARS-CoV-2 and COVID-19

T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant

SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

Authors showed that CD4+ and CD8+ T cell recognition of the Omicron spike was largely preserved in individuals vaccinated with Ad26.COV2.S, compared with ancestral virus

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Immunogenicity, lot consistency, and extended safety of rVSVΔG-ZEBOV-GP vaccine: a phase 3 randomized, doubleblind, placebo-controlled study in healthy adults

Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Authors used data from the ChAdOx1-nCoV-19 trial to determine antibody levels assocaited with protection against SARS-CoV-2. They showed that higher anti-spike IgG, anti-RBD IgG and neutralising antibody titres are all associated with lower risk of symptomatic disease

Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

The authors used a systems serology approach to characterise vaccineinduced antibodies in humans. They demonstrated that ChAdOx1 booster dose enhanced Fc-mediated functional antibody responses and anti-spike neutralising antibody titres

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Antibody-mediated protection against Ebola virus

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

MAIT cell activation augments adenovirus vector vaccine immunogenicity

Authors showed that MAIT cell-deficient mice displayed impaired CD8+ responses to adenovirus vaccine-encoded antigens and that MAIT cell activation in humans positively correlated with vaccine T-cell responses, suggesting an important role for MAIT cells in adenoviral vector immunogenicity

Protective mucosal immunity against SARS-CoV-2 after heterologous systemic primemucosal boost immunization

Authors showed that intranasal adenoviral vector vaccine boost (following an mRNA or DNA prime) induced mucosal IgA and enhanced mucosal neutralisation of virus

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebocontrolled, test-of-concept trial

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial

Novel prime-boost vaccine strategies against HIV-1

Prime-boost vaccine strategy against viral infections: mechanisms and benefits

Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people

Heterologous human immunodeficiency virus Type 1 primingboosting immunization strategies involving replicationdefective adenovirus and poxvirus vaccine vectors

Safety and immunogenicity of a heterologous primeboost ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a singleblind, randomised, non-inferiority trial

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, noninferiority trial

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen

The potential of adenoviral vaccine vectors with altered antigen presentation capabilities

Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope

Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule

Authors added the Toll-like receptors signalling molecule, TRAM, to an Ad vaccine which, when co-expressed with the antigen, increased trangene-specific CD8+ T cell responses in mice

Phase 2 Placebo-controlled trial of two vaccines to prevent Ebola in liberia

Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines

A replicating single-cycle adenovirus vaccine against Ebola virus

Newcastle disease virus-based vectored vaccine against poliomyelitis

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination